Medicamen Biotech: Financial Results - Quarter and Half year ended on September 30, 2026
Medicamen Biotech (MEDICAMEQ) filed a disclosure titled "Financial Results - Quarter and Half year ended on September 30, 2026". The company is valued at about ₹382 crore.
What happened
Medicamen Biotech (MEDICAMEQ) filed a disclosure with the exchanges on 13 November 2026 at 04:07 PM titled "Financial Results - Quarter and Half year ended on September 30, 2026".
Company snapshot
Medicamen Biotech is a micro-cap company, with a market value of about ₹382 crore.
The stock last traded at ₹281.7, against a 52-week range of ₹212.4–₹447.7 (37.1% below the high).
Before this filing the shares had moved −9.2% over the month and +13.7% over three months. Average daily turnover over the last 20 sessions was about ₹0.4 crore.
Promoters held 40.46% at the end of Q1 FY27. Foreign institutions owned 0.07% and domestic institutions 0.40%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 43 | 2.2 | 1.18 |
| Q2 FY26 | 47 | 2.7 | 1.56 |
| Q3 FY26 | 47 | 2.2 | 1.21 |
| Q4 FY26 | 61 | 3.9 | 3.28 |
| Q1 FY27 | 48 | 2.1 | 1.36 |
What history shows
This is not the company's first results disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 0.8% on average the next trading day and was down 2.6% on average after five days (2 filings with price data).
Market-wide, 11,743 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 43% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 14 Aug 2026 | Financial Results For The Quarter Ended On June 30, 2026. | −6.1% | −2.9% |
| 27 May 2026 | Audited Stabdalone & Consolidated Financial Results For The Quarter… | +4.5% | −2.4% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 13 November 2026: Board meeting — Financial Results.
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.